A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers by Stecca, Barbara & Ruiz i Altaba, Ariel
EMBO
open
A GLI1-p53 inhibitory loop controls neural stem cell
and tumour cell numbers
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited.Thislicensedoesnot
permit commercial exploitation or the creation ofderivativeworks without speciﬁc permission.
Barbara Stecca
1 and Ariel Ruiz i Altaba*
Department of Genetic Medicine and Development, University of
Geneva Medical School, Geneva, Switzerland
How cell numbers are determined is not understood.
Hedgehog-Gli activity is involved in precursor cell prolif-
eration and stem cell self-renewal, and its deregulation
sustains the growth of many human tumours. However, it
is not known whether GLI1, the ﬁnal mediator of Hh
signals, controls stem cell numbers, and how its activity
is restricted to curtail tumourigenesis. Here we have
altered the levels of GLI1 and p53, the major tumour
suppressor, in multiple systems. We show that GLI1 ex-
pression in Nestin
þ neural progenitors increases precur-
sor and clonogenic stem cell numbers in vivo and in vitro.
In contrast, p53 inhibits GLI1-driven neural stem cell
self-renewal, tumour growth and proliferation.
Mechanistically, p53 inhibits the activity, nuclear localisa-
tion and levels of GLI1 and in turn, GLI1 represses p53,
establishing an inhibitory loop. We also ﬁnd that p53
regulates the phosphorylation of a novel N’ truncated
putative activator isoform of GLI1 in human cells. The
balance of GLI1 and p53 functions, thus, determines cell
numbers, and prevalence of p53 restricts GLI1-driven stem
cell expansion and tumourigenesis.
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Introduction
A key unresolved issue in biology is how cell numbers are
determined during development, largely maintained in adult-
hood and deregulated in cancer. Hedgehog-Gli signalling is a
key intercellular communication pathway involved in many
aspects of development and cancer. During early brain devel-
opment, it modulates precursor proliferation in different
brain regions such as the neocortex, tectum and cerebellum
(e.g., Dahmane and Ruiz i Altaba, 1999; Dahmane et al,2 0 0 1 ;
Lien et al, 2006), while later on it regulates brain stem cell
lineages (e.g., Lai et al, 2003; Palma and Ruiz i Altaba, 2004;
Palma et al, 2005). It also drives rodent (Goodrich et al, 1997)
and human (Dahmane et al, 2001) brain tumourigenesis and
the self-renewal and survival of brain cancer stem cells
(Clement et al, 2007). This dual involvement of Hh-Gli
signalling in development and disease underlines its central
role in controlling precursor cell numbers in the brain and
other organs. It is not known, however, whether the level of
GLI1 is critical to determine stem cell numbers and how GLI1
activity is restrained to prevent tumour formation.
Here we have tested two hypotheses: (1) GLI1 is a central
determinant of stem cell numbers; (2) p53, the major human
tumour suppressor, which regulates stem cell and precursor
numbers (Gil-Perotin et al, 2006; Meletis et al, 2006), does so
by negatively modulating the activity of GLI1. Testing these
two ideas is important, as GLI proteins can integrate pattern-
ing and proliferative inputs in addition to HH signals
(Brewster et al, 2000; Palma and Ruiz i Altaba, 2004;
Kasper et al, 2006; Riobo ´ et al, 2006; Dennler et al, 2007),
as well as those from oncogenic RAS-MEK/AKT (Stecca et al,
2007); and p53 suppresses whereas GLI1 promotes tumour-
igenesis. We report that (1) the level of GLI1 determines the
number of neural stem cells in vivo, (2) GLI1 and p53 act in
an inhibitory loop, (3) endogenous GLI1 isoforms exist, and
(4) a novel N’D GLI1 isoform is subject to regulation by
phosphorylation in a p53-dependent manner. Our present
and previous data suggest a critical regulation of GLI1 func-
tion in stem cell lineages by oncogenes and tumour suppres-
sors, which is off-balance in disease.
Results
Elevation of GLI1 levels in neural progenitors results
in a larger brain with expanded progenitor populations
To enhance Gli1 activity in stem cell lineages in vivo,w e
developed doxycycline (dox) inducible bigenic mice using the
Nestin intron II driver (Nestin-4rtTA-IRES-LacZ driver;
Supplementary Figure 1), which is strongly expressed in
embryonic neural progenitors but only very weakly postna-
tally (Figure 1; Supplementary Figures 1–4 and not shown).
As a responder, we made a bidirectional GFPo-tetO-4myc-
GLI1 transgene by random insertion (one line) or by targeting
into the hprt locus (three lines). All bigenic lines showed the
same phenotypes, and we focused on perinatal phenotypes of
the ﬁrst line resulting from sustained embryonic dox admin-
istration (Supplementary Table 1; Supplementary Figure 1).
Double-transgenic (DT)-treated mice (DT
þdox), but not
untreated (DT
 dox) siblings or treated single transgenics,
expressed GLI1 and GFP in precursors and displayed larger
brains with hyperplasias of progenitor zones throughout from
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663forebrain to spinal cord (Figure 1A–D; Supplementary Figure
1 and not shown). The strength of the phenotype varied
within a litter. DT
þdox mice with a strong phenotype
(Figure 1) were embryonic lethal or died shortly after birth.
Surviving animals had milder alterations (Supplementary
Figure 3A). Three brain regions with strong phenotypes
(cortex, thalamus and cerebellum) and the spinal cord had
high levels of LacZ, GFP and Nestin and of GLI1 and
Figure 1 Enhanced GLI1 activity induces a larger brain with hyperplasias. (A–D)D T
þdox bigenic mice with strong phenotypes are perinatal
lethal exhibiting a larger brain than DT
 dox siblings, seen dorsally (A, B) or in sagittal sections after Xgal staining highlighting the expression of
the Nestin-4rtTA-LacZ driver (C, D) (see Supplementary Figure 1). (E–H) Phenotypes detected in cross section in the thalamus (Thal; E, F),
cerebellum (Cb) and medulla (Md; G, H) showing LacZ (Xgal) labelling (E–H), BrdU incorporation (G, H), GLI1 and Ptch1 (F) or GFP (H)
expression in DT
 dox and DT
þdox siblings as indicated. (I–K) HP1g
 /Nestin
þ/GFP
þ precursors from the ventricle (v) invade the parenchyma
through the cortical plate and expand near the pial (p) surface in the cingulate cortex (I, J). Invading GFP
þ cells associate with CD34
þ
endothelial cells in vessels as seen in a Z-stack confocal reconstruction (K) and a confocal image detail (K inset). (L–P) Phenotypic analyses in
cross sections of subventricular zone of the lateral ventricle (SVZ) (L) and thalamus (M–P) for the markers indicated. Myc-GLI1 was mostly
cytoplasmic and Prox1 nuclear (O inset). L shows a confocal image. Tissue is counterstained with eosin (e.g., C, D, M) and nuclei with DAPI
(e.g., I, L). Hip, hippocampus; Sc, spinal cord; Tct, tectum; vz, ventricular zone; Scale bar¼1.5mm (A, B), 1mm (C, D), 0.5mm (E–H), 100mm
(O inset, J, P), 200mm (I), 70mm (L; H inset), 14mm (K), 10mm (K inset), 0.6mm (M, N, O), 150mm (M inset).
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M and P; Supplementary Figures 2–4). The cerebellar exter-
nal germinal layer, which has the highest levels of endogen-
ous Gli1 (Dahmane and Ruiz i Altaba, 1999), was largely
unaffected, whereas the ventricular zone (VZ) was hyper-
plastic (Figure 1G and H; Supplementary Figure 3A, B). The
tectum (colliculi) was also larger but did not show convo-
luted tissue as the cerebellum, thalamus or medulla (Figure
1A–D; Supplementary Figure 1). Massive and highly invasive
precursor hyperplasias were also detected in the spinal cord
(Supplementary Figure 4).
Transgenic GLI1 induced B4–13-fold the activity of the
endogenous Hh-Gli pathway as assessed by the increased
expression of Gli1 and Ptch1 (Figure 2A; Supplementary
Figure 5). It also boosted 2–8-fold BrdU incorporation in a
region-speciﬁc manner (Figure 1G, H and P; Supplementary
Figure 2C, D, G, H). In the cortex and subventricular zone of
the lateral ventricle (SVZ), we found high GFP
þ, LacZ
þ,
Ptch1
þ, myc-GLI1
þ groups of cells streaming from the VZ to
the pial surface (Figure 1I and J; Supplementary Figure 2A–E,
I). These cells were HP1g
 , a heterochromatin (neuronal and
senescent cell) marker (Figure 1I); they expressed high levels
of Nestin (Figure 1J; Supplementary Figure 2B, E), associated
with CD34
þ vessels (Figure 1K) similarly to human gliomas
(Farin et al, 2006), and derived from Nestin
þ,G F A P
  VZ cells
(Figure 1L).
DT
þdox GFP
þ regions in thalamus and cerebellum showed
the highest proliferative levels (Figure 1G and H;
Supplementary 2G, H) with reduced (2–3-fold) apoptosis
(Supplementary Figure 3C). Massive, tumour-like hyperpla-
Figure 2 Gene expression and cellular behaviour in neurospheres and stem cells. (A) RT–qPCR analyses of P0 dissected tissues from cortex
(Ctx), thalamus (Thal) or cerebellum (Cb). qPCR values in all panels reﬂect ct values after normalisation with the geometrical mean of the
values of Gapdh, bactin and EFIa and shown as the DT
þdox/DT
 dox value ratios. See Supplementary Figure 5. (B) Phase contrast and
ﬂuorescence images of DT
þdox NS. (C–E). Histograms of the number of neurospheres (C, D) or BrdU
þ cells (E) as indicated. Primary spheres
were quantiﬁed per 250000 brain cells. (F) The level of GLI1 determines NS numbers. GLI1 expression values and secondary sphere number
were determined for the same samples. (G–I) Quantiﬁcation of the number (G), clonogenicity after MACS (H) and gene expression analyses (I)
by RT–qPCR of Prominin1
þ cerebellar stem cells (see Supplementary Figure 6B). Here and in all ﬁgures asterisks denote signiﬁcative changes
(Po0.05) and error bars are s.e.m. Scale bar¼80mm (B).
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sion were prominent in these regions (Figure 1F, H and M).
Hyperplasias showed little differentiation as assessed, for
instance, by exclusion of neuronal Prox1 (Figure 1N and
O), neuroblast NeuroD1 staining in dorsal thalamus
(Supplementary Figure 3D), or astrocytic GFAP expression
in cerebellum (not shown). A slight increase in the expres-
sion of the oligodendrocyte progenitor marker Pdgfra was
detected in thalamus (Supplementary Figure 3D). Unaffected
regions preserved differentiation (Supplementary Figure 2J).
As the strong phenotype is perinatal lethal, and we found that
transgenes are silenced B1–2 weeks after birth, it is unclear
whether such lesions could develop into frank tumours.
GLI1 upregulates an embryonic stem cell signature in
the brain and modulates different signalling pathways
Gene expression analyses by qPCR of different regions of
perinatal DT
þdox brains showed that GLI1 induced Shh-Gli
pathway components and targets including Shh, Gli1, Hip,
Ptch1, Snail1 and Igf2 (Figure 2A; Supplementary Figure 5).
It also upregulated a group of ‘stemness’ genes, including
Nanog, Sox2, Klf4, Nestin, Prominin1 (CD133) and Bmi1
(Figure 2A), which is reminiscent of that of human gliomas
(Clement et al, 2007). The changes in gene expression levels
were greatest in the cerebellum, consistent with phenotype
strength (Figure 1; Supplementary Figures 1–4), although each
region displayed overlapping yet context-dependent signatures.
DT
þdox brains also showed an increase in Notch (Hes1, Hes5,
Notch1, Jagged1) and the repression of BMP (Bmp2, Bmpr-Ia,
Bmpr-Ib) activity signatures (Figure 2A), with Bmpr-Ia and -Ib
being key determinants for stem cell responses to BMPs
(Panchision et al, 2001). Enhanced GLI1 may thus increase
the number of Nestin
þ stem cells reﬂected in the upregulation
of stemness genes involving modiﬁcation of Notch, BMP and
other (Igf2, Nodal, Hgf; Figure 2A) signalling pathways.
GLI1 induces an increase in the number of clonogenic
neural stem cells
Given the lack of unequivocal neural stem cell markers
in vivo, we tested for stem cell behaviour. Different parts of
DT
þdox brains showed an increase in the number of primary
and secondary clonal stem cell-derived neurospheres (NS), as
compared with DT
 dox brains, displaying a concomitant in-
crease in proliferation with unchanged apoptosis levels (Figure
2B–E and not shown). DT
 dox and DT
þdox NS remained
multipotent and DT
þdox produced 2–5-fold more neurons
than DT
 dox NS upon differentiation (Supplementary
Figure 6A). Efﬁcient NS formation from the cerebellum was
only obtained from DT
þdox mice (Figure 2C and D).
Importantly, we found a direct correlation between the
number of NS formed from single DT
þdox cerebella and the
level of GLI1 (Figure 2F) so that higher levels of GLI1
produced more NS. To further address the role of GLI1 in
stem cells in vivo, we analysed the number of stem cells
expressing Prominin1 (Lee et al, 2005) by MACS sorting
DT
þdox and DT
 dox cerebella. The number of cerebellar
Prominin1
þ stem cells in vivo increased B3-fold in DT
þdox
over DT
 dox (Figure 2G), showing the in vivo enhancement of
stem cell numbers by GLI1. As expected, the Prominin1
þ
fraction showed 4–6-fold increased clonogenicity over
Prominin1
  cells (Figure 2H).
Gene expression signatures of puriﬁed Prominin1
þ stem
cells from DT
þdox and DT
 dox E17.5 cerebella revealed an
enrichment of Gli1, Shh, Ptch1, Ptch2, Nanog and Hes1 and
low expression of BMP signalling components in DT
þdox
stem cells (Figure 2I; Supplementary Figure 6B), showing
an action of GLI1 in stem cells. Gene expression analyses of
whole E17.5 NS further supported the ﬁndings with dissected
brain and puriﬁed Prominin1
þ stem cells, although a num-
ber of genes showed variant expression (Supplementary
Figure 5), probably reﬂecting different cellular compositions.
Cooperation of GLI1 and p53 knock-down on neural
stem cell self-renewal and tumour growth
The downregulation of p21 and Puma, two p53 targets, in
Prominin1
þ stem cells of DT
þdox cerebella (Figure 2I) is
consistent with the ﬁnding that p53 negatively controls
neural stem cell numbers (Gil-Perotin et al, 2006; Meletis
et al, 2006). Because the perinatal lethality of DT
þdox mice
with strong phenotypes prevented us from analysing
DT
þdox;p53
 /  mice for the possible development of frank
tumours and further expansion of stem cell pools, we ﬁrst
tested for the role of p53 on GLI1-induced NS self-renewal.
E17.5 cortical and thalamic DT
 dox and DT
þdox NS, or wt
NS transduced with control or GLI1-expressing lentivectors
were further transduced with a control or an shRNA speciﬁc
for p53 (shp53). Enhanced GLI1 or knock-down (kd) of p53
increased the number of clones as expected, but importantly,
their simultaneous action was synergistic (Figure 3A). They
also increased proliferation and decreased apoptosis addi-
tively (Figure 3B and C). Wt postnatal SVZ NS transduced
with lentivectors expressing full-length GLI1 or shPtch1 (to
endogenously enhance the Shh-Gli1 pathway) alone and in
combination with shp53 yielded similar synergism in clono-
genicity and additive results in proliferation and apoptosis
(Figure 3D–F). p53 therefore antagonises GLI1 in the control
of neural stem cell self-renewal in NS of different brain
regions.
Following these ﬁndings, we tested whether enhanced
GLI1 cooperates with p53 kd in tumour growth. As all
patient-derived glioblastoma stem cell cultures that efﬁciently
grew in our hands were p53 mutant (M Vucikevic and ARA,
personal communication), and as NS from DT
þdox mice
extinguished transgene expression in vivo after transplanta-
tion (not shown), we used human U87 glioblastoma (p53 wt)
cells. These cells show the least number of genomic changes
among glioma cell lines (Li et al, 2008). Cells transduced with
lentivectors expressing GLI1 or GLI1 plus shp53 were grafted
intracranially and tumours removed when the mice showed
signs of neurological disease. Enhanced GLI1 expression
induced an acceleration of tumour development (Figure 3G
and H) and an increase in tumour weight as compared with
controls. p53 kd alone did not accelerate tumour develop-
ment, but it synergised with enhanced GLI1 levels (Figure 3G
and H). These results are consistent with the acceleration of
cerebellar tumours in Ptc1
þ/ ;p53
 /  mice as compared with
Ptc1þ/  siblings (Wetmore et al, 2001), although the bases
of such acceleration is unknown.
Balancing SHH-GLI and p53 activities in the control
of tumour cell numbers
As expected, kd of HH-GLI signalling with a validated
shSMOH (Clement et al, 2007; Stecca et al, 2007) or with
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2004; Stecca et al, 2007) decreased U87 cell proliferation and
enhanced apoptosis (Figure 4A–C). In contrast, p53 kd in-
creased proliferation of U87 cells (Figure 4A and B).
Interestingly, epistatic analyses revealed that shp53-enhanced
proliferation was blocked by both shSMOH and siGLI1 but
not by control lentivectors or control siRNAs (Figure 4A and
B) on the one hand, whereas on the other, cell death induced
by shSMOH was blocked by shp53 (Figure 4C), suggesting
mutual requirement.
Consistent with this idea, restoration of p53 function in
p53-mutant brain tumour cells (U251 glioma and Daoy me-
dulloblastoma) reduced, and enhancement of GLI1 levels
increased, their proliferation, but these effects were mutually
compensated (Figure 4D). Similarly, oxaliplatin treatment of
U87 cells increased endogenous p53 levels through the DNA
damage response and decreased cell proliferation (Figure 4E),
but this proliferative defect and the level of induced phospho-
p53 were attenuated in cells with enhanced GLI1 levels
(Figure 4E), further suggesting a balance of levels and
activities. Enhanced GLI1 levels, however, also induced
hallmarks of DNA replication stress (Gorgoulis et al, 2005)
that are known to lead to enhanced p53 function in different
scenarios: increasing the number of 53BP1 protein foci in
293T cells and increasing the number of phospho-Chk2
þ
cells in DT
þdox hyperplastic thalamic and cerebellar regions
(Supplementary Figure 7A, B). Together, these data suggest
an endogenous antagonistic relationship between p53 and
GLI1 but also the possible induction of p53 function by GLI1
through the DNA replication stress response.
Figure 3 Synergistic control of neural stem cell self-renewal and xenograft growth by GLI1 and kd of p53. (A–F) Quantiﬁcation of the
behaviour of E17.5 NS from cortex (Ctx) or thalamus (Thal) (A–C) or of ﬁrst week postnatal SVZ NS (D–F) testing for clonogenicity (A, D),
proliferation (B, E) and apoptosis (C, F). Cells were derived from DT mice and treated as indicated or were wt NS transduced with lentivectors
as shown. (G) Dorsal views of mouse brains uninjected or injected with transduced U87 cells as indicated. Tumour contours (t) are denoted.
(H) Quantiﬁcation of tumour weights versus time after injection; n¼5 for each condition. c¼control lentivector. Scale bar¼0.4mm (G).
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with p53 function require endogenous Gli1
The blockade of shp53-mediated increased cell proliferation
by interference with endogenous SMOH or GLI1 function
(Figure 4A and B) suggested that interference with p53
frees endogenous GLI1 from negative regulation, leading to
cell overproliferation. As an in vivo assay to analyse this idea,
we tested for the role of Gli1 in tumours induced by blockade of
p53. Frog embryos expressing dominant negative (Thr
280)p 5 3
(dnp53), which inhibits endogenous p53 function, develop
epidermal tumours (hyperplasias) (Wallingford et al, 1997).
Co-injection of a control antisense morpholino oligonucleotide
(MO) along with dnp53 did not modify its tumour-inducing
activity (n¼18/19 tadpoles with tumours; Figure 4F–H). In
contrast, coinjection with a proven MO speciﬁc for frog Gli1
(Dahmane et al, 1997, 2001; Nguyen et al,2 0 0 5 )r e d u c e dt h e
development of dnp53-induced tumours by B40% (n¼21/37).
As a control for MO speciﬁcity, injection of Gli1 MO (n¼6/24),
but not the control MO (n¼27/27), reduced tumour develop-
ment by co-injected human GLI1 by 66% (Figure 4F–H;
Dahmane et al, 1997, 2001; Nguyen et al,2 0 0 5 ) .B l o c k a d eo f
endogenous Gli1 changed the distribution of the descendants of
the injected blastomeres from clumped in tumours to evenly in
t h ee p i d e r m i s ,a p p r o p r i a t ef o rt h en o r m a lf a t eo ft h ei n j e c t e d
Figure 4 Mutual requirements of p53 and GLI1 in proliferation and apoptosis. (A–C) Histograms of the changes in cell proliferation (A, B) or
apoptosis (C) after altering SMOH, GLI1 or p53 levels by lentiviral transduction or siRNA lipofection in U87 cells. (D) Compensatory effects in
cell proliferation in U251 and Daoy cells by GLI1 and p53. (E) Left: Rescue of the anti-proliferative effect of p53 induction by oxaliplatin (48h)
by transduced GLI1 in U87 cells. Comparisons are with untreated (0) control (c) except where noted. Right: Western blot of the levels of p53
and phospho-serine15 p53 induced by oxaliplatin with or without exogenous GLI1. Hsp90 is used as control. (F–H) Quantiﬁcation (F) and
whole-mount side views (G, H) of Xgal-stained stage 32 tadpoles facing the centre of each panel with epidermal hyperplasias (arrows; top rows,
G, H) or the normal distribution of cells in the epidermis (bottom rows, G, H) as indicated. Scale bar¼0.6mm (G, H).
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(through injection) therefore bypasses proliferative restrictions
imposed by p53, and blockade of endogenous p53 unleashes
the proliferative activity of endogenous Gli1.
p53 negatively regulates the activity, nuclear
localisation and levels of GLI1
Gene expression analyses of NS expressing both GLI1 and
shp53 revealed context-speciﬁc differences in the effect of
p53 kd on GLI1-regulated genes (Supplementary Figure 8),
for instance, increasing the expression of the stemness genes
Prominin1, Bmi1 and Nanog, as well as p16, Gli1, Hes1, Hes5
and other Notch components in different regions, whereas
decreasing p21 in cortex and cerebellum, all as compared
with NS expressing GLI1.
To elucidate how p53 alters the genetic program induced
by GLI1, we ﬁrst asked whether p53 affects GLI1-dependent
transcription in GLI-dependent luciferase reporter assays.
shp53 increased 2–3-fold the activity of GLI1 in wt postnatal
mouse SVZ NS, and this was reproduced in human U87 and
in 293T cells (Figure 5A and B; Supplementary Figure 9A).
dnp53 behaved similarly and p53 kd also augmented the
diminished activity of N’D forms of GLI1 and GLI2
(Figure 5A). shp53 did not endow GLI3 or its C’D repressor
form (GLI3R) with activity (Figure 5A; Supplementary Figure
9A), suggesting that it does not act by inhibiting repressor
function. Conversely, restoring p53 activity in U251 and Daoy
cells (both p53 mutant) decreased GLI1 reporter activity and
the levels of exogenous GLI1 in a concentration-dependent
manner (Figure 5C; Supplementary Figure 9B). p53 did not
affect the levels of GLI1 mRNA in co-transfected cells (not
shown). Enhanced transcriptional activity by shp53 was
correlated with two-fold enhanced nuclear localisation of
GLI1, of N’D forms of GLI1 and GLI2 but not of GLI3,
GLI3R or of a nuclear targeted NLS-Gli1 (Ruiz i Altaba,
1999; Figure 5D and E). p53 thus appears to promote the
localisation of GLI1, and possibly of GLI2, in the cytoplasm,
where it can be degraded by the proteasome (Huntzicker
et al, 2006).
To test whether p53 generally inhibits GLI1 levels, we
analysed GLI1 protein in different contexts. E17.5 thalamic
NS of DT
þdox brains were transduced with control or shp53
lentivectors and kept in the presence of dox. Western blots
with a commercial anti-GLI1 antibody (a-GLI1
B420; Cell
Signalling) showed that p53 kd induced a 30% increase in
full-length GLI1 (4160KD) and a three-fold increase of a
shorter form running ±130KD (Figure 5F), quantiﬁed by
densitometry. Similarly, analysis of postnatal wt SVZ NS for
endogenous mouse Gli1 with an anti-GLI1 antibody to the
C-terminus (a-GLI1
803 818; GeneTex) showed a 40% increase
in full-length mouse Gli1 (4160KD) and a 2.3-fold increase
in a shorter form running at B115KD (Figure 5G). As control,
and as a-GLI1
B420 does not recognise mouse Gli1
(Figure 6C), we used a-GLI1
803 818 to probe extracts of P10
wt cerebellum, adult (B4mo) Cb and a Ptch1
þ/ ;p53
 / 
medulloblastoma (MB) (Figure 5H). As expected from the
transient perinatal expansion of cerebellar GLI1
þ granule
neuron progenitors and the strong expression of GLI1 in MB
(Dahmane and Ruiz i Altaba, 1999; Dahmane et al, 2001), the
full-length and the shorted 115KD form were clearly detected
at P10 and were nearly undetectable in adult cerebellum,
whereas the full-length form was 14-fold and the 115KD form
6.5-fold more abundant in MB than at P10 (Figure 5H).
GLI1 represses p53
The mutual compensatory effect of GLI1 and p53 (Figure 4D)
and the dominance of GLI1 kd over p53 kd (Figure 4B) raised
the possibility that in addition to the negative regulation of
GLI1 by p53, p53 itself could be under GLI1 regulation.
Analyses of p53 in GLI1 kd cells (see below) revealed that
endogenous p53 is under the control of endogenous GLI1 as
assessed by the levels of total p53 and of active phospho-
serine15 p53 (p53-P) in cells lipofected with siGLI1 versus siC
(Figure 6E). The kd of endogenous GLI1 function increased
p53 B5-fold and phospho-serine15 p53 B2-fold. This indi-
cates that in addition to the inhibition of GLI1 by p53
described earlier, endogenous GLI1 regulates the levels of
endogenous p53, suggesting a negative regulatory loop.
Enhanced GLI1 levels can inhibit p53 regulation in vitro
through the activation of the p53 inhibitor Hdm2 (Abe et al,
2008). We ﬁnd that Mdm2, the mouse homologue of Hdm2, is
greatly enhanced in DT
þdox versus DT
 dox brains (Figure 6F),
extending this possible mechanism of action to an in vivo
context.
The inhibitory loop between GLI1 and p53 is consistent
with the inversely reciprocal levels of GLI1 and p53 observed
in two primary glioblastoma stem cell cultures (Figure 6G;
Clement et al, 2007). The level of GLI1 correlated with their
proliferation rate (Figure 6G). GBM12 harbours a p53 gene
with a frameshift mutation corresponding to aa 209 (M
Vukicevic and ARA, unpublished) and predicted to encode
an unstable protein as no p53 or phospho-serine15 p53
proteins were detected (Figure 6G). GBM13 expresses full-
length p53 with an R-4H substitution at aa 158 within the
DNA-binding domain (M Vukicevic and ARA, unpublished)
predicted to yield a protein with compromised transcriptional
activity (Kato et al, 2003). Whereas full-length GLI1 protein
was barely detectable (not shown), GMB12, which has no
p53, showed higher levels of GLI1
130 (see below) than
GBM13, which expresses p53 with reduced activity.
Identiﬁcation of human GLI1 isoforms
Given the existence of isoforms of GLI1 (Figure 5F–H),
reminiscent of those of other Gli proteins, we investigated
the possibility that p53 affects their formation or function in
human cells. Transfection of U251 glioma cells with full-
length myc-tagged GLI1 (Figure 6A, left) revealed the
full-length form running at 4160KD (GLI1
FL) plus one
predominant smaller N-terminal tagged form running at
B110KD (GLI1
110) after probing the western with a-N’ myc
tag antibodies. This form has been proposed to act as a C’D
repressor (Ruiz i Altaba, 1999). Treatment with cyclohexi-
mide to block de novo protein synthesis showed increased
stability of GLI1
100 over GLI1
FL (Figure 6A, left). The produc-
tion of distinct GLI1 isoforms could be limiting in different
cells or context dependent as GLI1 transfected in U87 cells
yielded the full-length protein but only traces of smaller
products (Supplementary Figure 9C). This variance also
suggests that the stable products seen in U251 are not non-
speciﬁc, ubiquitous degradation products.
To directly monitor GLI1 isoforms, we developed an afﬁ-
nity-puriﬁed, speciﬁc antibody (a-GLI1
412 427) against a do-
main immediately C-terminal to the zinc ﬁngers of human
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Reprobing the anti-myc tag westerns in human U251 cells
with a-GLI1 revealed the same full-length and 110KD iso-
forms plus a novel B130KD form at similar exogenous levels
(Figure 6A, right). This form lacks the myc tags and thus the
N-terminus. Endogenous GLI1 was expressed at much lower
levels (see below). Treatment with cycloheximide showed
differential isoform stability: GLI1
130 peaked at 1h, GLI1
100
was largely stable with a 1.6-fold increase at 4h, and GLI1
FL
decayed 2.4-fold at 4h (Figure 6A, right). As the 130KD N’D
species cannot give rise to the B100 KD C’D form, this
suggests a precursor-product relationship between the
GLI1
FL and the GLI1
130 form and between GLI1
FL and
GLI1
100 (Figure 6B), with GLI1
1004GLI1
130bGLI1
FL stabili-
ties, arguing against the ﬁrst two being non-speciﬁc degrada-
tion products.
Figure 5 Regulation of GLI1 by p53. (A–C) Quantiﬁcation of GLI-dependent luciferase reporter assays (A–C) and inhibition of GLI1
FL by p53
(C). Luciferase units are GLI reporter ﬁreﬂy/renilla control ratios with the level induced by GLI1 equated to 100%. p53 was used at 1/0.25,
1/0.5, 1/1 maintaining equal amounts of GLI1 (triangle in C). (D, E) Representative images (D) and quantiﬁcation of GLI nuclear localisation in
U87 cells (E). (F–H) Western blots showing the expression of transgenic GLI1 in thalamic DT
þdox NS (F), endogenous Gli1 in postnatal SVZ NS
(G) and endogenous Gli1 in P10 and adult cerebella as well as in a Ptch1
þ/ ;p53
 /  medulloblastoma (MB; H). Transduction with shp53
lentivectors leads to an increase in the abundance of transgenic GLI1 (F) and endogenous Gli1 (G). p53 and Hsp90 are used as controls. Scale
bar¼15mm (D).
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used two commercial polyclonal antibodies against GLI1:
a-GLI1
B420 made to the same region as our a-GLI1
412 427
and the C-terminal antibody a-GLI1
803 818. Western blots of
P0 DT
þdox and DT
 dox brain extracts revealed the presence of
GLI1
FL, GLI1
130 and GLI1
100 only after induction with dox
with a-GLI1
412 427 and a-GLI1
B420, conﬁrming speciﬁcity
(Figure 6C). a-GLI1
412 427 also picked up a non-speciﬁc
band in mouse brain extracts (asterisk, Figure 6C). In con-
trast, a-GLI1
803 818 picked up GLI1
FL and GLI1
130 but not
GLI1
100 (Figure 6C) (and minor background bands), consis-
tent with the C’ truncation of GLI1
100 and the N’ truncation of
GLI1
130 (Figure 6B). Probing with a different polyclonal
C-terminal antibody (a-GLI1
805 820; Chemicon) made to the
same region gave the same results (not shown).
To analyse whether endogenous human GLI1 isoforms
exist, we probed western blots of U87 cells that are known
to harbour an active HH-GLI pathway (Clement et al,2 0 0 7 )
with our own and seven commercial a-GLI1 antibodies (see
Materials and methods). Only a-GLI1
412 427 yielded the ex-
pected pattern of endogenous isoforms (Figure 6D;
Supplementary Figure 9D and not shown) seen previously
(Figure 6A and C). The other antibodies revealed various
non-consistent patterns (not shown). Thus, whereas many
a-GLI1 antibodies recognise enhanced levels of GLI1, only
a-GLI1
412 427 recognises endogenous human GLI1.
Figure 6 GLI1 protein isoforms and endogenous repression of p53 by GLI1. (A) Transfected myc-GLI1 isoforms detected as indicated in
samples treated with cycloheximide (CHX) as shown. GLI1
FL migrates 4160KD. (B) Deduced relationship of GLI1
130 and GLI1
100 to GLI1
FL,
and location of Ab epitopes and of the transactivating (TA) domain. (C) Analyses of human GLI1 protein in transgenic P0 mice as indicated. All
three antibodies used recognise GLI1
FL and GLI1
130, but only those to the domain immediately C-terminal to the zinc ﬁngers (ZF in B) recognise
GLI1
100.( D) Analysis of GLI1 isoforms in human cell lines and in a GBM stem cell culture (gliomasphere). (E) GLI1 kd with a speciﬁc siRNA for
8h, but not a control siRNA, depletes all three isoforms in U87 cells, while enhancing total and phospho-serine15 p53 (p53-P) levels. Non-
speciﬁc bands are denoted by asterisks. (F) Levels of Mdm2 in the blot shown in panel C middle for GLI1 and Hsp90. (G) Comparison of the
levels of GLI1
130, p53, phospho-serine15 p53 and HSP90 in two gliomaspheres that proliferate at different rates.
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(GMB12; Clement et al, 2007) and a panel of human tumour
cell lines with a-GLI1
412 427 revealed all isoforms with
GLI1
1304GLI1
1004GLI1
FL abundances (Figure 6D). GLI1
130
was most prevalent in metastatic melanomas (which harbour
active GLI1; Stecca et al, 2007), and it was consistently
detected as a doublet (Figure 6D). Endogenous human
GLI1
FL and GLI1
100 do not have N’ myc tags and are therefore
slightly smaller than their tagged exogenous counterparts
(Figure 6A and C). Commercial westerns further conﬁrmed
the presence of a GLI1 B130KD form in various human
tissues and tumours with a possible tumour-speciﬁc altera-
tion in GLI1 (Supplementary Figure 9E, F).
To verify the identity of the isoforms recognised by
a-GLI1
412 427, we used RNAi to kd endogenous GLI1.
Lipofection of a speciﬁc siRNA previously proven to target
GLI1 mRNA (siGLI1; Sanchez et al, 2004; Clement et al,2 0 0 7 ;
Stecca et al, 2007) but not of a control siRNA (siC), knocked-
down GLI1
FL two-fold, GLI1
130 13-fold and GLI1
100 4.4-fold.
The levels of HSP90 were unaltered (Figure 6E).
Constructs that approximate the GLI1 N’D and C’D
isoforms have divergent functions
To address the possible functional signiﬁcance of GLI1 iso-
forms, we analysed the activity of GLI1 constructs that
approximate N’D GLI1
130 and C’D GLI1
100 (GLI1N’D and
GLI1C’D; Ruiz i Altaba, 1999). Consistent with the presence
of the transcriptional activation domain close to the C-termi-
nus (Figure 6B; Yoon et al, 1998), these constructs behaved as
weak activators or repressors, respectively, in GLI1-depen-
dent reporter assays (Ruiz i Altaba, 1999) (Figure 5A). The
strength of GLI1N’D activator was context dependent, as its
activity was 1.2-fold weaker than GLI1
FL in melanoma
SkMel2 cells but 3.4-fold stronger in prostate cancer LNCaP
cells (not shown), and similarly or more active in other cell
types (Yoon et al, 1998; Sasaki et al, 1999).
p53 and HH signalling regulate the status of GLI1
130
The existence of GLI1 isoforms raised the possibility that p53
could alter their genesis or levels. Treatment of U87 cell
extracts in vitro with l phosphatase followed by western
blotting with a-GLI1
412 427 revealed the conversion of the
upper band of the GLI1
130 doublet to the lower one (Figure 7A
and D), indicating that the upper band is a phosphoform of
GLI1
130 (GLI1
130P). GLI1
100 decreased slightly but did not
change size (Figure 7A), and the GLI1
FL band became fainter
(Figure 7A and not shown), suggesting that it might also be
affected although its rarity made further assessment not
possible. Consistently, however, the level of exogenous
GLI1
FL decreased with lambda phosphatase treatment, sug-
gesting that it is phosphorylated and highly unstable in its
dephosphorylated form (Supplementary Figure 9G). GLI1
FL
and GLI1
130P, but not of GLI1
130, were detected in a phospho-
protein selected pool, conﬁrming their phosphorylated status
(Supplementary Figure 9H).
The kd of p53 in U87 cells increased the levels of GLI1
130
B6–8-fold at the expense of GLI1
130P. Treatment with l
phosphatase conﬁrmed that GLI1
130P is the phosphoform of
GLI1
130 (Figure 7B and D). Endogenous GLI1
FL and GLI1
100
were modestly increased by p53 kd, consistent with the
increase in exogenous GLI1
FL levels by p53 kd (Figure 5F;
Supplementary Figure 9C). Similar results were obtained in
glioma D54 (p53 wt) cells (not shown). The data raise the
possibility that GLI1
130P is a latent and stable form, the
conversion of which to its unphosphorylated, labile and
active form (GLI1
130) is antagonised by p53.
To begin to investigate the mechanisms regulating the
balance of GLI1
130 and GLI1
130P, we focused on phosphatase
(PP) activity given the suggested involvement of PP2A in Hh
signalling (Krishnan et al, 1997). U87 and U251 cells were
treated with low doses of okadaic acid (OA, 10nM, 16h) and
extracts subjected to western blotting. OA is a serine/threo-
nine protein phosphatase inhibitor with high afﬁnity for
PP2A and much lower afﬁnities for PP1 and PP2B. OA
increased (50–80%) GLI1
130P in control U87 cells
(Figure 7D). In p53 kd cells, which have increased levels of
GLI1
130, OA treatment reversed the 130P/130 ratio
(Figure 7D), decreasing GLI1
130 by B40–50% and augment-
ing GLI1
130P B2-fold. Similar results were obtained in U251
cells (not shown). The very low levels of endogenous GLI1
FL
prevented us from assessing changes after OA treatment (not
shown).
To correlate the levels of GLI1
130P with transcriptional
activity, endogenous GLI-dependent reporter function was
measured in OA-treated U87 cells. OA reduced reporter levels
by 60–70% and abolished the increase induced by shp53
(Figure 7E), paralleling the western blot results. Moreover,
OA treatment repressed the endogenous levels of both GLI1
and PTCH1 mRNAs (Figure 7F), conﬁrming the downregula-
tion of the endogenous HH-GLI pathway.
We also analysed GLI1 isoforms after increasing the
strength of HH signalling through kd of the major negative
regulators PTCH1 or SUFUH, by RNAi (with shPTCH1 or
shSUFUH). Such interference resulted in a B2.5-fold upregu-
lation of GLI1
130 at the expense of GLI
130P mimicking the
effect of p53 kd (Figure 7B and C). Enhanced HH signalling
also increased GLI1
FL and GLI1
100 levels by 3–5-fold and
2.5–3-fold, respectively (Figure 7B and C).
These results suggested that OA should inhibit the prolif-
erative effects of enhanced HH pathway activation. The
increase in BrdU incorporation in U87 cells driven by
shSUFUH was reverted by OA treatment (Figure 7G). OA
also inhibited untransduced U87 cell proliferation
(Figure 7G), which is known to depend on an active HH-
GLI pathway (Clement et al, 2007). GLI1
130 thus appears to
depend on the action of PP2A or a similar enzyme, being
positively regulated by HH signalling and inhibited by p53
(Figure 7H).
The kinases and mechanisms that yield GLI1
130P are not
known. cAMP-dependent Protein Kinase A (PKA) blocks HH
signalling (e.g., Epstein et al, 1996), and its enhancement
with forskolin (FK), a selective activator of adenyl cyclase,
inhibits GLI1 activity (Ruiz i Altaba, 1999; Kaesler et al,
2000; not shown). PKA promotes GLI1 phosphorylation
and its localisation in the cytoplasm, where it can be de-
graded (Sheng et al, 2006). We therefore tested whether
enhanced PKA activity by FK treatment could have the
same effect on GLI1
130 as inhibiting endogenous PP2A and/
or similar phosphatase activity by OA. FK treatment of wt
U87 cells yielded similar levels of GLI1
130P as control or OA-
treated cells (Figure 7D). However, FK treatment of cells
expressing shp53 did not reverse the GLI1
130P/GLI1
130 ratio
to the extent that OA treatment did. Rather, GLI1
130 was
largely eliminated by FK treatment (Figure 7D). The data
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antagonises GLI1 activity include the degradation of the
GLI1
130 activator form.
Discussion
Here we show that GLI1 is under negative control by p53 in
multiple systems, and that GLI1 and p53 form a novel
homeostatic inhibitory loop that normally controls precursor
and stem cell numbers. We propose that its modiﬁcation
alters the behavior of stem cell lineages leading to increases
or decreases in cell numbers, such as those in cancer or
aging, respectively.
The level of GLI1 activity determines brain size and
neural stem cell self-renewal
GLI1 is the last mediator of HH signals, acts as a nexus to
integrate non-HH signals such as RAS, and is an emerging
Figure 7 Regulation of GLI1 isoforms and phosphorylation status of GLI1
130 by p53 and HH signalling. (A) Effects of l phosphatase treatment
(þlPPase) or of shp53, shPTCH1 or shSUFUH. Endogenous p53 and SUFUH levels are shown. (B, C) Enlargements of the ±130KD area in
(A). The %GLI1
130 calculated by densitometry in relation to total GLI1
130þGLI1
130P values is green. The fold increase in GLI1
130/control is blue.
(D) Effects of shp53, and of okadaic acid (OA) and forskolin (FK) for 16h, on GLI1
130 isoforms in U87 cells. lPPase treatments and p53 and
p53-P levels are shown as controls. (E) Quantiﬁcation of endogenous GLI—luciferase assays in control U87 cells and after 16h OA treatment in
wt or shp53-expressing cells. (F) RT–qPCR of control and OA-treated U87 cells after 12h showing decreased expression of GLI1 ( 10
 4) and
PTCH1 ( 10
 3). (G) Quantiﬁcation of BrdU incorporation in control and shSUFUH-transduced U87 cells treated or untreated with OA.
(H) GLI1-p53 inhibitory loop model. (I) Proposed regulation of GLI1
130 by PP2A or a similar enzyme, HH and p53 activities.
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(reviewed in Ruiz i Altaba et al, 2007). We ﬁnd that the level
of GLI1 in transgenic mice controls precursor and stem cell
numbers in multiple brain regions. Consistent with this, GLI1
induces a stemness signature that includes Nanog, Klf4 and
Sox2, which parallels that of glioma cancer stem cells
(Clement et al, 2007) and includes genes involved in repro-
gramming (Takahashi and Yamanaka, 2006). As the majority
of GFP
þ cells in the DT
þdox SVZ are not GFAP
þ, a marker of
postnatal semiquiescent stem cells (Doetsch et al, 1999),
enhanced GLI1 levels could thus increase the number of
actively dividing stem cells. Such increases in brain stem
cells and precursors are concomitant with the region-speciﬁc
modulation of several signalling pathways. Notably, GLI1
upregulates Notch and downregulates critical BMP signalling
components, in line with the requirement of Notch–Jagged
signalling in neural stem cell self-renewal (Nyfeler et al,
2005), and the pro-differentiative action of BMP signalling
on stem cells (Panchision et al, 2001). Moreover, the strong
upregulation of Hes1 that we detect in vivo and in cerebellar
stem cells is consistent with it being a Notch and Gli target
(Ingram et al, 2008; V Wallace, personal communication) and
is interesting in view of its recent implication in the preven-
tion of senescence (Sang et al, 2008).
We suggest a role for endogenous Gli1 in neural stem cells
as enhanced GLI1 levels expand the number of clonogenic
stem cells, and Prominin1
þ stem cells from DT
þdox cerebella
upregulate endogenous Gli1 while downregulating Gli2 and
Gli3 (this work). Moreover, even though it is dispensable for
mouse development (Park et al, 2000), acute interference
with endogenous Gli1 in mouse hippocampal NS decreases
clone numbers (Galvin et al, 2008), and SVZ Gli1
 /  mutant
mouse NS show a 40% reduction in secondary clonogenicity
(M Vukicevic and ARA, personal communication). Gli1 may,
therefore, normally contribute to the control of stem cell
lineage longevity, acting to balance antagonising p53 func-
tion, consistent with the ﬁnding that loss of p21, a p53 target,
transiently enhances the self-renewal of neural stem cells but
then leads to their premature exhaustion (Kippin et al, 2005).
The balance of antagonistic GLI1 and p53 functions
regulates cell numbers
GLI1 is tightly controlled by multiple mechanisms, and here
we show that a novel critical modulator of GLI1 in precursors,
stem and tumour cells is p53, a multifunctional tumour
suppressor (Harris and Levine, 2005). Our data suggest a
model for a novel homeostatic mechanism in which p53 and
GLI1 form a regulatory loop (Figure 7H). Here, any inappropri-
ate elevation of GLI1 would induce the DNA damage (replica-
tion stress) response, which leads to activation of p53, and
elevated p53 would then decrease GLI1 activity. At the same
time, however, endogenous GLI1 antagonises endogenous p53,
possibly through its regulation of BMI1 or its activation of the
p53 inhibitor Hdm2/Mdm2 (Abe et al, 2008; this work).
Normal organ-speciﬁc regulation of this loop may act to
maintain precursors and stem cells in their appropriate
numbers to insure life-long persistence and constant organ
size, while preventing tumourigenesis. Interestingly, we
found that synergistic enhancement of stem cell numbers
by GLI1 and p53 kd increased expression of p16
INK4a.A s
increasing p16
INK4a levels mark aging neural stem cells
(Molofsky et al, 2006), such synergistic action may induce
neural stem cell aging, possibly leading to their eventual
exhaustion, consistent with the self-renewal deﬁcit in NS
lacking Gli1 (see above). The p53-GLI1 regulatory loop
might thus not only normally act to maintain size and
shape, preventing cancer, but might also act to time aging.
Control of GLI1 by p53
Detailed analyses of exogenous and endogenous human GLI1
reveal that GLI1 exists in different forms: GLI1
FL, GLI1
130 and
GLI1
100 (Figure 6A), with the ﬁrst two likely acting as
activators and the last one as a weak repressor. GLI1
130
lacks the N-terminus of GLI1
FL, and as it is produced from
the full-length cDNA, it is distinct from a differential splice
form of GLI1 lacking 128aa from the N-terminus (Shimokawa
et al, 2008). Indeed, this spliced form is exceedingly rare
(B19-fold less abundant than GLI1
FL on average in cell lines
(Shimokawa et al, 2008), whereas GLI1
130 is 410-fold more
abundant than GLI1
FL. The greater abundance of GLI1
130 over
GLI1
FL is consistent with the deduced absence in GLI1
130 of
two inhibitory sites in the N-terminus of GLI1
FL: an N’ degron
(Huntzicker et al, 2006) and a key binding site for the GLI1
antagonist SUFUH (Dunaeva et al, 2003).
Our data suggest that p53 acts to inhibit GLI1 function in
two ways:
(1) p53 represses the transcriptional activity of GLI1
FL by
reducing its nuclear localisation and protein levels. This type
of regulation is seen with exogenous transfected GLI1 and
may be operative with the very rare endogenous GLI1
FL
protein and possibly with GLI1
130.
(2) p53 promotes the phosphorylation of the endogenous
novel N’D GLI1
130 isoform. We ﬁnd that GLI1
130 is predomi-
nantly found in a phosphorylated state (GLI1
130P) and suggest
that non-phosphorylated GLI1
130 is a labile activator, the
abundance of which correlates with activity (Figure 7I).
Exogenous GLI1
FL also appears to be phosphorylated and
endogenous GLI1
FL might behave similarly, being subjected
also to this second mode of regulation.
Concerning the regulation of GLI1
130, p53 could act, directly
or indirectly, to antagonise a protein phosphatase, favouring
the inactive and more stable GLI1
130P. Treatment with low
doses of OA increases GLI1
130P and decreases GLI1
130.A sO A
has a higher afﬁnity for PP2A than to PP1 or PP2B, and the
B56e subunit of PP2A is required for Gli1 function in frog
embryos (Rorick et al, 2007), the phosphatase responsible for
the dephosphorylation of GLI1
130P may be PP2A.
The mechanism of N’D truncation, phosphorylation site(s)
and kinases involved in the genesis of GLI1
130P remain to be
determined. PKA is an important antagonist of HH signalling
(Epstein et al, 1996), it inhibits GLI1 activity (Ruiz i Altaba,
1999; Kaesler et al, 2000), and we show that activation of
endogenous PKA through FK treatment results in the degra-
dation of GLI1
130. We suggest that although the formation of
GLI1
130 depends on phosphatase activity, its degradation may
involve PKA. We also suggest that p53, unlike PKA, acts to
antagonise GLI1
130 by promoting GLI1
130P.
As activation of HH signalling (by inhibition of PTCH1 or
of SUFUH) also modulates and appears to depend on the level
and phosphorylation status of GLI1
130, GLI1 is regulated
transcriptionally (Lee et al, 1997) and posttranscriptionally
by HH signals.
In contrast to the positive role of GLI1
130, GLI1
100 might act
as an immediate and tonic negative feedback, as it may have
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GLI3, but unlike this (Pan and Wang, 2007), it is not inhibited
by Hh signalling.
It is possible that GLI2 and GLI3 share similarities with the
novel regulation of GLI1 we describe here, as N’D forms are
strong transcriptional activators and Gli2 is an early mediator
of Hh signals (Sasaki et al, 1999), OA treatment can inhibit
Shh signalling (Krishnan et al, 1997) and FK treatment
phosphorylates Gli2 (Riobo ´ et al, 2006).
Imbalance of GLI1 and p53 activities in disease
The homeostatic balance of the GLI1-p53 regulatory loop that
we have uncovered appears to be critical. Whereas its imbal-
ance in favour of p53 could affect stem cell lineages and aging
(Serrano and Blasco, 2007), imbalance in favour of GLI1
appears to be predominant in cancer and cancer stem cells.
For example, glioma cancer stem cells require sustained HH-
GLI function (Clement et al, 2007) and gliomas frequently lack
p53 (e.g., Ohgaki and Kleihues, 2007). We suggest that loss of
p53, which is a common event in human cancers, unleashes
the normally restricted proliferative and self-renewing activities
of GLI1, leading to an expansion of cancer stem cells and
derived progenitors. Tumor suppressors may thus normally act
to regulate stem cell lineages. In addition to p53 control, the
positive regulation of GLI1 activity by the major human
oncogenes (RAS, AKT; Stecca et al, 2007), and its negative
regulation by the tumour suppressor PTEN (Stecca et al, 2007),
highlights the exquisite regulation of GLI1 activity and provides
a rationale for its widespread involvement in human cancer.
Materials and methods
A full account of all methods is given in Supplementary data.
Transgenic mice, neurospheres and cell lines
Doxycycline-regulated GLI1 transgenic (GFPo-tetO-4GLI1) mice
were crossed with Nestin-4rtTA-IRES-LacZ mice to obtain bigenic
mice (Supplementary Figure 1). NS were prepared from brains as in
Palma and Ruiz i Altaba (2004), transduced with lentivectors and
analysed 4–5 days afterwards.
Plasmids, lentiviral vectors and RNA interference
Transfections were at equimolar amounts unless otherwise speci-
ﬁed with pCS2-Myc-tagged human GLI1, GLI1DN’, GLI2DN’, GLI3,
GLI3R (GLI3C’DClaI), frog Gli1, frog NLSGli1 (Ruiz i Altaba, 1999),
wt human p53, human dnp53 (p53
Thr280), pCMV-EGFP or
pCMV-LacZ.
Lentiviral vectors were pLV-CTH-shSMOH (Clement et al, 2007);
pLV-CTH-shPTCH1 with targeting sequence 50-GCACTATGCTCCTT
TCCTC-30; pLV-WPXL-shp53 (targeting human p53); pLV-Sico-shp53
(targeting mouse p53 Addgene); pLV-KO.1-puro-shSHFUH (Sigma);
and pLV-GLI1 was in pLV-Lox-CWor pLV-TWEEN. siRNA sequences
for human GLI1 and control siRNA were as described in Sanchez
et al (2004).
Luciferase reporter assays and isolation of Prominin1
þ cells
GLI-binding site luciferase reporter assays were as described in
Sasaki et al (1999). Cortical and SVZ NS were transfected by
nucleofection (Amaxa). Cells of DT
þdox and DT
 dox brains were
dissociated, labelled with Prominin1-microbeads and puriﬁed in a
magnetic-activated cell-sorting column (Miltenyi Biotec).
Intracranial xenografts and RNA microinjection
Lentivector-transduced U87 human glioblastoma cells (10
5)w e r e
grafted using a stereotaxic apparatus (L2,P1,D2 relative to Bregma).
Synthetic RNA and MO (Genetools) microinjection into four-cell frog
embryos was performed as described in Dahmane et al (1997, 2001).
Immunohistochemistry, in situ hybridisation and PCR
Cryostat sections were Xgal stained or immunostained with
antibodies as noted. In situ hybridisation with digoxygenin-labelled
RNA probes was as described in Dahmane et al (1997, 2001).
Quantitative rtPCR with cDNA was carried out at 601C using iQTm
SYBR green mix (Bio-Rad).
Western blotting
GLI1 protein was detected in westerns with anti-myc tag or anti-
GLI1 antibodies and ECL chemiluminescence (Amersham), or
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Scientiﬁc) for endogenous GLI1.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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